Analyst Report: TER
1. EXECUTIVE SUMMARY
Teradyne (TER) closed at $380.29 on Tuesday October 13, down 11.63% from $430.32 on October 6, and the research brief identifies no single company-specific negative event behind the decline. The weakness came over four main down sessions (October 6, 7, 8 and 12), with October 12 the largest at -4.68%. Quiver Quantitative's automated note attributes the October 12 fall to sector-wide weakness and profit-taking and found no new negative Teradyne release or filing; Quiver describes this as the most likely explanation, so the evidence is thin. Peers fell by similar or smaller amounts over the same period (AMAT -12.45%, LRCX -9.82%, Q -8.03%, KLAC -6.82%), which fits that reading. The $300M FormFactor investment was announced after the October 12 close and so cannot account for that session's drop. The stock remains up 83.44% year to date and sits just below its 50-day average, with third-quarter results the next test.
2. THE CATALYST
The brief finds no company-specific trigger. The timeline below ties the available evidence to each session using the daily closes.
| Session | Close | Change | Volume | Evidence in brief |
|---|---|---|---|---|
| Oct 2 | $449.04 | +8.00% | 3,399,000 | Prior run-up, no cause in brief |
| Oct 6 | $430.32 | -3.20% | 2,010,000 | No company catalyst found; Titan HP launch (Business Wire) |
| Oct 7 | $411.78 | -4.31% | 2,396,200 | Wider-coverage titles mention a Titan HP launch and a Cathie Wood ARK sale; articles not opened. Argus raised its target to $488 |
| Oct 8 | $398.72 | -3.17% | 3,393,200 | No catalyst found |
| Oct 9 | $402.68 | +0.99% | 1,813,700 | Small rebound |
| Oct 12 | $383.85 | -4.68% | 2,729,400 | Quiver cites sector weakness and profit-taking; FormFactor deal came after the close |
| Oct 13 | $380.29 | -0.93% | 2,737,300 | No catalyst found |
The main company news in the window is the Teradyne investment of $300M in FormFactor, subject to customary closing conditions and regulatory approvals (Investing.com and the FormFactor press release, October 12). TipRanks reports a private placement of about 2.2 million FormFactor shares, expected to close in the fourth quarter of FormFactor's fiscal 2026. FORM rose in extended trading (TradingView/Seeking Alpha), while TER traded modestly lower after hours (CNN quote page). That after-hours move suggests, as inference, that investors did not view the deal as a positive for Teradyne. One source says Teradyne agreed to the investment on October 6, but only the October 12 release date is verified.
3. COMPANY PROFILE
Teradyne designs and sells automated test systems and robotics products. It reports through Semiconductor Test, Robotics and Other segments, and the Semiconductor Test business covers wafer-level, device-package and system-level testing for automotive, industrial, communications, consumer, smartphone and cloud applications. Market capitalisation is $59.45bn. The stock trades on a forward P/E of 32.6 and a trailing P/E of 52.2.
Recent results were strong. MarketBeat reports second-quarter 2026 revenue of $1.33bn, up 103.9% year over year, and EPS of $2.47 against a $2.09 consensus. Quiver Quantitative reports third-quarter revenue guidance of $1.2bn to $1.3bn. Business Wire announced two products in the window: the Titan HP burn-in platform on October 6 and the UltraFLEXplus S Series for edge AI on October 12. CEO Gregory Smith described the FormFactor deal in the joint release as building a more complete, validated path to production for shared customers.
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? The brief shows no deterioration in the business over the window. Quiver found no new negative Teradyne release or filing, and the one analyst action in the period, Argus raising its target to $488 on October 7 with a bullish rating, was positive. The price action tracks the sector, so the evidence favours a valuation and positioning reset over a company-specific reassessment. The October 12 explanation rests on a single automated note, which is weak evidence.
Peers. Applied Materials fell 12.45%, slightly more than Teradyne, and Lam Research fell 9.82%. Qualcomm's ticker Q is shown in the facts as a peer at -8.03%, and KLA fell 6.82%. Wider-coverage titles on October 7 and 13 also show other test and equipment names falling, though the brief did not open them.
Comparable episodes. Baird downgraded TER to neutral from outperform with a $420 target on August 21, and the shares fell about 2% that day (MarketScreener). A Tickeron blog, a single low-quality source, reports a one-day drop of about 14% in late April after a second-quarter guidance miss that followed a record first-quarter beat, with valuation cited as a factor. The current decline is more gradual and has no identified negative trigger.
Bull case. Revenue doubled year over year in the second quarter, earnings beat consensus, and the shares remain 14.25% above their level 20 sessions ago. Argus holds a $488 target. The FormFactor stake extends Teradyne's position with shared customers.
Bear case. The stock has risen 83.44% this year and trades at 52.2 times trailing earnings, which leaves little room for disappointment. The reaction after hours to the FormFactor deal was lukewarm. MarketBeat reports an average analyst target of $396.80, only about 4% above the last close, although the Yahoo Finance forecast page shows $446.47, and the two likely reflect different data sets and dates. Morningstar's decreased rating on October 1 is unconfirmed.
5. TECHNICAL SNAPSHOT
The close of $380.29 sits just below the 50-day average of $383.43 and well above the 200-day average of $342.35. It is 22.0% under the 52-week high of $487.72 set on June 30 and far above the 52-week low of $134.74. The lowest close in the table is $380.29, the latest, so no lower support level appears in the recent closes; the nearest overhead reference points are the 50-day average of $383.43 and the $383.85 close of October 12. Volume of 2,737,300 was 1.09x the 50-session average, and the heaviest sessions in the window came on the way down (3,393,200 on October 8) and on the October 2 rally (3,399,000), so selling has been orderly rather than a rush for the exits.
6. RISK FACTORS
- Sector rotation: profit-taking in semiconductor and AI-linked equipment names continues to pressure the group, and Teradyne has moved with its peers.
- Valuation: a forward P/E of 32.6 leaves the shares exposed to any guidance shortfall, as the April episode shows.
- Deal execution: the FormFactor investment needs regulatory approval and is expected to close in the fourth quarter of FormFactor's fiscal 2026.
- Data conflicts: the facts panel lists earnings on October 21, while Teradyne's October 13 release gives Tuesday October 27 at 4:30 p.m. ET or later. The company date is the better source, and the date should be confirmed.
- Unverified items: the ARK sale and the Morningstar rating change rest on headlines only.
Upcoming dates: third-quarter results on October 27 (company release; the panel's estimates are EPS of 2.05 and revenue of $1.26bn, against guidance of $1.2bn to $1.3bn).
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks): the stock trades with the semiconductor equipment group, and the peer moves suggest direction will follow the sector until results. A recovery through the 50-day average of $383.43 would ease the pressure, while a further slide extends a decline that has no company-specific cause.
Medium term (1-3 months): the third-quarter report on October 27 is the main driver. Results and guidance that hold the second-quarter growth rate would support the Argus-type targets, and a miss against the $1.2bn to $1.3bn guide would test the valuation. Management commentary on the FormFactor deal and the new edge-AI and burn-in products will also matter.
Long-term thesis: unchanged on the evidence in the brief. The one-week decline came with no identified deterioration in the business, and the growth, earnings beat and product pipeline cited above remain in place. This is analysis, not personal financial advice.